About Avelas
Avelas Biosciences is a clinical-stage drug-device company focused on developing and commercializing pegloprastide (also known as AVB-620) with the goal of revolutionizing cancer surgery with real-time margin detection. In a prospective trial in women with early-stage breast cancer undergoing a lumpectomy, intraoperative imaging of pegloprastide detected up to 75% of the positive margins that resulted from standard-of-care techniques. Beyond breast cancer, pegloprastide has the potential to significantly improve outcomes in a variety of other cancer surgeries.

Latest News
-
Oct 18, 2021
Avelas Makes Senior Appointments and Provides Update on Pegloprastide Phase III Clinical Program
Read more -
Apr 29, 2021
Avelas Biosciences Presents Phase 2, Period 2 Data in Virtual Poster Session at the 22nd Annual Meeting of The American Society of Breast Surgeons
Read more -
Dec 14, 2020
Avelas Receives FDA Breakthrough Therapy Designation for Pegloprastide (AVB-620) for Use During Breast Cancer Surgery
Read more